Brainstorm Cell Therapeutics/$BCLI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Ticker
$BCLI
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
29
ISIN
US10501E3009
Website
BCLI Metrics
BasicAdvanced
$8.4M
-
-$2.01
0.21
-
Price and volume
Market cap
$8.4M
Beta
0.21
52-week high
$2.50
52-week low
$0.72
Average daily volume
2.5M
Financial strength
Current ratio
0.214
Quick ratio
0.157
Long term debt to equity
-1.703
Total debt to equity
-23.736
Interest coverage (TTM)
-159.84%
Profitability
EBITDA (TTM)
-12.08
Management effectiveness
Return on assets (TTM)
-222.36%
Return on equity (TTM)
170.46%
Valuation
Price to book
-1.12
Price to tangible book (TTM)
-1.12
Price to free cash flow (TTM)
-0.765
Free cash flow yield (TTM)
-130.73%
Free cash flow per share (TTM)
-138.58%
Growth
Earnings per share change (TTM)
-56.90%
3-year earnings per share growth (CAGR)
-40.67%
10-year earnings per share growth (CAGR)
-14.14%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Brainstorm Cell Therapeutics stock?
Brainstorm Cell Therapeutics (BCLI) has a market cap of $8.4M as of June 30, 2025.
What is the P/E ratio for Brainstorm Cell Therapeutics stock?
The price to earnings (P/E) ratio for Brainstorm Cell Therapeutics (BCLI) stock is 0 as of June 30, 2025.
Does Brainstorm Cell Therapeutics stock pay dividends?
No, Brainstorm Cell Therapeutics (BCLI) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Brainstorm Cell Therapeutics dividend payment date?
Brainstorm Cell Therapeutics (BCLI) stock does not pay dividends to its shareholders.
What is the beta indicator for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics (BCLI) has a beta rating of 0.21. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.